Shanghai, China - MicroPort^® CardioFlow Medtech Corporation (hereinafter referred to as MicroPort^® CardioFlow", stock code: 02160.HK) announced that its self-developed VitaFlow Liberty^® Transcatheter Aortic Valve and Retrievable Delivery System (hereinafter referred to as "VitaFlow Liberty^®"), a new generation product for Transcatheter Aortic Valve Implantation (TAVI), has been approved by the Argentine National Administration of Drugs, Foods, and Medical Devices (ANMAT).

Since VitaFlow^® Transcatheter Aortic Valve System (hereinafter referred to as " VitaFlow^® "), the first-generation TAVI product of MicroPort^® CardioFlow, was implanted commercially overseas for the first time in Dr. Julio Mendez Hospital of Argentina in August 2021, MicroPort^® CardioFlow has successfully carried out TAVI operations in several hospitals in Argentina.

In October, 2021, the largest cardiovascular academic conference in Latin America-"SOLACI-CACI 21 "and MicroPort^® CardioFlow jointly held an online seminar called" Challenges in TAVI-Severe CAD and Coronal Occlusion ". Dr. Diego Grinfeld and Dr. Jose Alvarez, presidents of Argentine Society of Interventional Cardiology, co-chaired the seminar, and experts from Argentina and China shared their experiences in TAVI treatment. This online meeting not only laid a good academic foundation for the sustainable development of MicroPort^® CardioFlow in Latin America, but also set a new academic benchmark in the field of structural heart disease in China and Latin America.

VitaFlow Liberty^® is the world’s only electric retrievable transcatheter aortic valve system, offering outstanding stability during procedure and hemodynamics post-procedure that will improve the quality of life for patients with aortic valve disease. It inherits the advantages of the VitaFlow^® in terms of valve design, featuring a hybrid density self-expanding stent, bovine pericardial leaflets, and a high double-layer PET skirt design. This design offers robust radial force, improved coaxiality during deployment, and effectively reduces the incidence of perivalvular leakage post-procedure. Moreover, its breakthrough upgraded delivery system incorporates a unique and innovative double-reinforced spiral structure that ensures rapid, stable, and precise release and retrieval. This system also provides flexibility, allowing for 360-degree bending of the valve segment.

The endorsement of VitaFlow Liberty^® will help MicroPort^® CardioFlow to enter more overseas potential markets more quickly. In the future, MicroPort^® CardioFlow will continue to adhere to the mission of "providing trustworthy and universal access to state-of-the-art total solutions to treat structural heart diseases", further give play to the advantages of the platform, accelerate the launch of innovative products with international competitiveness, and promote the "China-created" total medical solution for structural heart disease in the international mainstream product competition.